Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3714029 Target Snapshot

Lysyl oxidase homolog 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,037Compounds
63Assays
2Approved Drugs
1,521.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Lysyl oxidase homolog 2 shows clinical signal disease relevance led by cirrhosis of liver. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y4K0. Start with cirrhosis of liver, then reuse UniProt Q9Y4K0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cirrhosis of liver, then reuse UniProt Q9Y4K0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cirrhosis of liver

Lysyl oxidase homolog 2 shows clinical signal disease relevance led by cirrhosis of liver. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cirrhosis of liver because it currently carries clinical signal support. Linked drugs include SIMTUZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lysyl oxidase homolog 2 as ChEMBL target CHEMBL3714029, mapped to UniProt Q9Y4K0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lysyl oxidase homolog 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3714029
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y4K0
Lysyl oxidase homolog 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Lysyl oxidase homolog 2 is the right protein anchor across sources, using UniProt Q9Y4K0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cirrhosis of liver is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLysyl oxidase homolog 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ9Y4K0
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLysyl oxidase homolog 2
UniProt AccessionQ9Y4K0
Component TypeProtein
Sequence Length774 aa

Lysyl oxidase homolog 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Lysyl oxidase homolog 2, mapped to UniProt Q9Y4K0. Sequence length is 774 aa.

Mapped IDQ9Y4K0
Review nameLysyl oxidase homolog 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Lysyl oxidase homolog 2 shows clinical signal disease relevance led by cirrhosis of liver. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
cirrhosis of liver
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMTUZUMAB
Clinical signal Phase II
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMTUZUMAB
Clinical signal Phase II
fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugLENUMLOSTAT
Clinical signal Phase II
idiopathic pulmonary fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMTUZUMAB
Clinical signal Phase II
myelofibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMTUZUMAB
Clinical signal Phase II
pancreatic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMTUZUMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cirrhosis of liver because it currently carries clinical signal support. Linked drugs include SIMTUZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecirrhosis of liver
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC501,520.0
KI1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4457578 8.4 IC50 3.981 Preclinical
CHEMBL4448713 8.3 IC50 5.012 Preclinical
CHEMBL4556859 7.9 IC50 12.59 Preclinical
CHEMBL4458907 7.7 IC50 19.95 Preclinical
CHEMBL4467234 7.7 IC50 19.95 Preclinical
CHEMBL4531065 7.7 IC50 19.95 Preclinical
CHEMBL4581458 7.7 IC50 19.95 Preclinical
CHEMBL4582216 7.6 IC50 25.12 Preclinical
CHEMBL4456063 7.55 IC50 28.0 Preclinical
CHEMBL4515085 7.55 IC50 28.0 Preclinical
Distribution

pChEMBL Value Distribution

36
5.0
88
5.5
133
6.0
234
6.5
134
7.0
11
7.5
4
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DISULFIRAM
CHEMBL964
Approved 1951
Properties Compare Identifier
Assay Landscape

Assay Landscape

63
Total Assays
442
Tested Compounds
2
Assay Types
Binding — 62 assays, 442 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 38 210 6.5
single protein format 17 172 6.4
assay format 7 60 5.9
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine